<DOC>
	<DOCNO>NCT02750202</DOCNO>
	<brief_summary>Large genital wart frequently diagnose general gynaecology oncology clinic South Africa . Medical destructive therapy small wart generally effective , however unique problem pose large extensive genital wart easily solve treatment affected patient remain challenge . Recurrences common especially among immune-compromised woman . This study test whether give quadrivalent human papilloma virus ( HPV ) vaccine woman extensive genital wart prior surgical treatment improve outcome . Investigators hypothesize pre-treatment HPV vaccine play role control malignant benign HPV disease woman without HIV infection stimulation antibody response . In addition , HPV type associate disease study woman receive HPV vaccine placebo .</brief_summary>
	<brief_title>Effectiveness Study Human Papilloma Virus ( HPV ) Vaccines Prevent Recurrence Genital Warts</brief_title>
	<detailed_description>Patient selection : Female patient refer present genital wart site eligible evaluated inclusion exclusion criterion . Women clinically severely immune-compromised include study , HIV negative HIV infect woman include . Seventy-five woman large recurrent genital wart recruit study 2 site South Africa . Recruitment : Women genital wart evaluate inclusion study . Those fit inclusion criterion without exclusion criterion fully inform invited participate . The first target recruit first seventy-five consecutive eligible patient sign write consent ; recruitment study do least 24 month . First clinical visit : - Evaluation genital lesion : On study entry tumour size position document graphically photographically viral type vulva wart cervix do use Roche Linear Array test . - Evaluation immune status : HIV status CD 4/CD 8 count record test serum collect antibody test . Cervical disease clinical significance exclude treatment offer relevant . - Randomization : Patients randomize receive either quadrivalent HPV Hepatitis B vaccine . - Vaccination : The participant assign test group administer quadrivalent HPV vaccine three dos recommend manufacturer . Participants assign control group receive Hepatitis B vaccine three dos recommend manufacturer . Follow-up clinical visit : week 8 , week 16 week 24 : - Evaluation genital lesion : Three follow visit schedule two month apart time lesion size record . - Evaluation immune status : After month 6 third visit , serum collect antibody level test . - Treatment decision : According clinical response measure month six onwards , locally destructive surgical treatment allow accord preference clinician determine clinical factor . Follow treatment : - Follow do six monthly interval . - Evaluation genital lesion : At visit lesion size determine document . HPV type cervical vulval lesion repeat least . - Further treatment wart : If need , repeat surgery and/or local destruction allow document . These around week 48 week 72 , study exit Study exit : - Participants exit study week 72 . - In absence harm determine interim analysis suggest participant disease history , researcher unblinded participant status study exit alternative vaccine offer woman .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Female patient &gt; 16 year Presence vulvo vaginal genital wart : large tumour diameter &gt; 3 cm OR Tumour labium minora labia majora OR bilateral &gt; 1 cm side OR Tumour vagina/cervix well vulva &gt; 1 cm lesion HIV negative HIV infect CD4 â‰¥ 300 cells/mm3 OR viral load control OR anti retroviral ( ARV ) compliant &gt; 6 month Pregnant plan pregnancy within 6 month Not able comprehend study method able attend study visit Previous HPV vaccination Active know opportunistic infection malignancy include Pneumocystis pneumonia ( PCP ) , Pulmonary tuberculosis ( PTB ) , oesophageal Candida Kaposi sarcoma lymphoma Known allergy vaccine content vaccine Previous radiation genital wart</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Genital wart</keyword>
	<keyword>HPV type</keyword>
	<keyword>HPV vaccine</keyword>
	<keyword>Cervical cytology</keyword>
	<keyword>Therapeutic vaccine</keyword>
	<keyword>Quadrivalent HPV vaccine</keyword>
</DOC>